Landscape Capital Management L.L.C. Has $1.34 Million Stake in Indivior PLC $INDV

Key Points

• Landscape Capital Management L.L.C. significantly increased its holdings in Indivior PLC by 78.1% during the first quarter, now owning 140,137 shares valued at approximately $1.34 million.
• Indivior reported a strong earnings performance with $0.51 earnings per share for the last quarter, exceeding analysts' expectations of $0.26 per share, alongside revenues of $302 million compared to estimates of $239.43 million.
• Wall Street analysts are optimistic about Indivior, with several raising their target prices, including Craig Hallum which set a new target of $34.00 and maintained a "buy" rating.

Landscape Capital Management L.L.C. grew its position in Indivior PLC (NASDAQ:INDV - Free Report) by 78.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 140,137 shares of the company's stock after purchasing an additional 61,455 shares during the period. Landscape Capital Management L.L.C. owned approximately 0.10% of Indivior worth $1,336,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company's stock worth $9,327,000 after purchasing an additional 958,132 shares in the last quarter. Tejara Capital Ltd acquired a new position in Indivior during the first quarter valued at approximately $1,157,000. Nuveen LLC bought a new position in Indivior in the first quarter valued at approximately $793,000. Vanguard Group Inc. grew its stake in Indivior by 1.6% in the first quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company's stock valued at $43,765,000 after purchasing an additional 71,539 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Indivior by 123.9% during the 1st quarter. XTX Topco Ltd now owns 50,437 shares of the company's stock worth $481,000 after purchasing an additional 27,906 shares in the last quarter. Institutional investors own 60.33% of the company's stock.

Indivior Trading Up 0.2%

Shares of NASDAQ:INDV traded up $0.06 during trading on Wednesday, reaching $24.66. 1,663,179 shares of the stock were exchanged, compared to its average volume of 1,819,075. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $25.00. The stock has a 50-day moving average price of $19.25 and a 200-day moving average price of $13.74.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%.The business had revenue of $302.00 million during the quarter, compared to analysts' expectations of $239.43 million. Indivior has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Jefferies Financial Group started coverage on shares of Indivior in a research note on Tuesday, July 22nd. They set a "buy" rating and a $20.00 price objective on the stock. HC Wainwright initiated coverage on shares of Indivior in a research note on Wednesday, August 6th. They issued a "buy" rating and a $27.00 target price for the company. Finally, Craig Hallum lifted their price target on Indivior from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. Based on data from MarketBeat.com, Indivior has an average rating of "Buy" and an average price target of $22.00.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.